Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) has been running upwards in recent tradingh as volume increases significantly. Now that the extra D is off the ticker and the RS well behind it CELZ is surging north with a flurry of form 4s filed as insiders buy.
Microcapdaily has covered CELZ many times in the past especially at times when the stock has moved. CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is a growth market. According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023.
Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is a commercial-stage biotechnology company focused on Urology and Neurology using stem cell treatments. The company’s team consists of leading international researchers in regenerative medicine with a “science-first” approach to treatments ensuring that all of its treatments are proven to be both safe and effective.
CELZ is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility and related issues. It holds a patent for its erectile dysfunction (“ED”) treatment and was granted a license by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, a non-profit biomedical research and education institute (“LABIOMED”), for the infertility treatment. It has also filed a patent application focused on physical manifestations of female sexual arousal disorder, as an extension of the work with stem cell therapies for ED.
Creative Medical is currently in the commercial stage of its bone marrow based stem cell treatment for Erectile Dysfunction known as CAVERSTEM, which is being marketed both nationally, and internationally. Earlier this year the Company formed the subsidiary CaverStem International LLC for the purpose of commercializing its erectile dysfunction technology to international physicians.
To Find out the inside Scoop on CELZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
CaverStem™ received positive reception at international urology conference. Dr. Alexander Gershman stated “I am very impressed by the strong endorsement we have been receiving from colleagues attending the American Urological Association conference. Since beginning to offer the CaverStem™ procedure in December 2017 we have treated multiple patients of which approximately 90% have reported positive improvements. These are all patients for which pharmacological interventions such as Viagra and Cialis do not work. rWhenever a new procedure is introduced to the community, it is fundamentally important to obtain the support of our peers, and to share our findings with our peers. We are enthusiastic by the interest in CaverStem™ by the American and International Urology Community.”
On April 20 CELZ announced receipt of a Quayle Action on its patent application #15/652213 entitled Methods for Treatment of Premature Ovarian Failure and Ovarian Aging using Regenerative Cells. The patent covers use of mesenchymal stem cells, a class of adult stem cells, for use in treatment of ovarian failure and ovarian aging.
Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto/Creative Medical Technology Hol)
This patent is a substantial milestone for the Company given that subsequent to filing, several academic groups published the ability of mesenchymal stem cells to treat ovarian failure in animal models.1,2
“We are pleased by the issuance of these broad claims, which not only cover a clinically-used family of stem cells, but also the cells which produce blood vessels, called Endothelial Progenitor Cells (EPC),” said Thomas Ichim, Ph.D co-inventor and Chief Scientific Officer. “Mesenchymal stem cells isolated from a wide variety of tissues such as bone marrow, adipose tissue, umbilical cord and even teeth, have been used in clinical trials for other diseases. Given the availability, practicality and strong safety record of this class of cells, we are in a position to choose from many developmental possibilities.”
We have a Monster Pick Coming. Subscribe Right Now!
Currently moving up the charts CELZ is fully reporting OTCBB, has minimal cash in the treasury, little revenues and $10 million in current liabilities. CELZ is an exciting Company developing in small caps; CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB. Now that the extra D is off the ticker and the RS well behind it CELZ is surging north with a flurry of form 4s filed as insiders accumulate. We will be updating on CELZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CELZ.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CELZ either long or short and we have not been compensated for this article.